NPHLA Daily
NPHLA Daily
Thursday, October 22, 2026 · 4-minute read
Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.
Top development today
What changed today in Regulatory: 1 safety alert
NPHLA tracked 1 new official record on this desk today: 1 safety alert. First: Wedgewood Pharmacy Issues Recall of Certain Compounded Veterinary Medications Within Expiry Due to Potential Potency Issues
Metabolic signal
What changed today in Metabolic: 1 new study
NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in Clinics and research in hepatology and gastroenterology: “Dose-Response Profiles in Incretin and Multi-Agonist Obesity Pharmacotherapy”.
Regulatory signal
Wedgewood Pharmacy Issues Recall of Certain Compounded Veterinary Medications Within Expiry Due to Potential Potency Issues
SWEDESBORO, N.J., (October 21, 2026) - Wedgewood Pharmacy LLC ("Wedgewood") is recalling certain compounded veterinary medications within expiry at the provider/customer level due to inconsistencies in the reliability of certain…
AI & Technology signal
What changed today in AI & Technology: 1 new study
NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in JMIR formative research: “Knowledge, Attitudes, and Practices of Malaysian Pharmacists Regarding AI Adoption: Cross-Sectional Study”.
One thing worth watching
Comments close: Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and…
October 29, 2026 — verified from the Federal Register comments_close_on.
5 things to know
- What changed today in Regulatory: 1 safety alert
- What changed today in AI & Technology: 1 new study
- What changed today in Metabolic: 1 new study
- Wedgewood Pharmacy Issues Recall of Certain Compounded Veterinary Medications Within Expiry Due to Potential Potency Issues (U.S. Food and Drug Administration (MedWatch))
- Dose-Response Profiles in Incretin and Multi-Agonist Obesity Pharmacotherapy (Clinics and research in hepatology and gastroenterology)
Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.